Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Growth in Short Interest

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 158,023 shares, a growth of 20,081.7% from the June 15th total of 783 shares. Based on an average daily volume of 30,391 shares, the days-to-cover ratio is currently 5.2 days. Approximately 0.2% of the company’s shares are short sold.

Ascentage Pharma Group International Trading Up 5.7%

Shares of AAPG traded up $1.07 during midday trading on Friday, hitting $19.97. 3,586 shares of the stock were exchanged, compared to its average volume of 7,054. Ascentage Pharma Group International has a 52-week low of $16.36 and a 52-week high of $48.45. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The stock has a fifty day simple moving average of $19.04 and a 200 day simple moving average of $22.97.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of hedge funds and other institutional investors have recently bought and sold shares of AAPG. UBS Group AG grew its position in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter worth about $391,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Finally, XY Capital Ltd grew its holdings in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AAPG. BTIG Research reaffirmed a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price on the stock. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $46.43.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.